Urologix, a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy technology to urologists to provide a in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), has appointed Brian Smrdel as its chief financial officer effective May 10, 2010.
Urologix said that Mr Smrdel is expected to report to the company’s chief executive officer, Stryker Warren, who was recently the corporate controller of Angeion, a St Paul, Minnesota-based medical technology company.
Following Mr Smrdel’s appointment, Rebecca Weber will continue with Urologix as the director of finance. Ms Weber has been a part of the Urologix finance team since March 2005, first as the company’s financial analyst, then as its manager reporting and controls, and since April 2008 as its controller and director of finance.
Prior to his position at Angeion, Mr Smrdel was the manager, worldwide financial planning and analysis at PepsiAmericas, a manufacturer, distributor and seller of a portfolio of beverage products in the US, Central Europe and the Caribbean. Before this position, Mr Smrdel held various financial positions at companies including Land O’Lakes and Target Corp.
Mr Warren, said: “In addition to his accounting experience in a public medical technology company, Brian brings to Urologix a strong background in financial analysis, planning and strategy. We are confident Brian’s significant talents will contribute to our efforts to grow Cooled ThermoTherapy as the standard of care for the in office treatment of BPH.
“We thank Rebecca for her willingness to rise to the challenges of the role over the last two years and are very pleased she will be continuing as the director of finance. Her leadership, along with her technical skill and deep knowledge of our business, will certainly help Brian in his transition to our chief financial officer.”